Bristol-Myers Squibb Company (BMY, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals. Bristol-Myers Squibb Company has a market cap of $150.15 billion; its shares were traded at around $64.05 with a P/E ratio of 29.25 and P/S ratio of 4.31. The dividend yield of Bristol-Myers Squibb Company stocks is 2.61%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years.
For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.
The reported diluted earnings per share was $2.01 for the year, a decline of 33.2% from the previous year. Over the last five years Bristol-Myers Squibb Company had an EPS growth rate of 14.2% a year. The Bristol-Myers Squibb Company had a decent operating margin of 22.62%, compared with the operating margin of 22.69% a year before. The 10-year historical median operating margin of Bristol-Myers Squibb Company is 22.50%. The profitability rank of the company is 9 (out of 10).
At the end of the fiscal year, Bristol-Myers Squibb Company has the cash and cash equivalents of $12.3 billion, compared with $6.9 billion in the previous year. The company had no long term debt, compared with $5.6 billion in the previous year. The interest coverage to the debt is 9. Bristol-Myers Squibb Company has a financial strength rank of 6 (out of 10).
At the current stock price of $64.05, Bristol-Myers Squibb Company is traded at close to its historical median P/S valuation band of $61.90. The P/S ratio of the stock is 4.31, while the historical median P/S ratio is 4.19. The stock gained 34.27% during the past 12 months.
For the complete 20-year historical financial data of BMY, click here.
